Dasan Pharmaceutical has secured a 13 billion Won pre-IPO investment, aimed at strengthening its financial position and accelerating global market entry.

Target Information

Dasan Pharmaceutical, a leading Contract Development and Manufacturing Organization (CDMO) in South Korea, has successfully secured a pre-IPO investment amounting to 13 billion Korean Won (approximately 10 million USD). This strategic investment is expected to bolster the company's market value and expedite its entry into global markets.

Dasan has developed a robust capacity for the comprehensive development and production of pharmaceutical products, ranging from active pharmaceutical ingredients to finished goods. The company has established a strong foothold in the chronic disease market, particularly for hypertension treatments, utilizing its proprietary high-tech formulation technologies.

Industry Overview in South Korea

The pharmaceutical sector in South Korea has been experiencing significant growth, driven by advancements in biotechnology and an expanding domestic market. As the count